On Friday the vaccine maker bharat biotech said that the clinical trials on animals of covaxin has been successful. This is a great indication.
“Bharat Biotech proudly announces the animal study results of COVAXIN – These results demonstrate the protective efficacy in a live viral challenge model,” tweeted the Hyderabad-based firm.
One group was administered a placebo while three groups were immunised with three different vaccine candidates at 0 and 14 days. All the macaques were challenged with SARS-CoV-2 14 days after the second dose. The protective response was observed with increasing SARS-CoV-2 specific IgG and neutralising antibody titres from third week post-immunisation,” it said.
“Viral clearance was observed from bronchoalveolar lavage fluid, nasal swab, throat swab, and lung tissues at 7 days post-infection in the vaccinated groups. No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group which showed features of interstitial pneumonia and localisation of viral antigen in the alveolar epithelium and macrophages by immunohistochemistry.